Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 187 of the 188 references it cites were found in a registry or an index, and 1 are not checked yet.

Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia

Open access
Renee Ruhaak, L, van der Laarse, Arnoud, Cobbaert, Christa M · 2019 · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine

Abstract

An elevated low-density lipoprotein cholesterol concentration is a classical risk factor for cardiovascular disease. This has led to pharmacotherapy in patients with atherosclerotic heart disease or high heart disease risk with statins to reduce serum low-density lipoprotein cholesterol. Even in patients in whom the target levels of low-density lipoprotein cholesterol are reached, there remains a significant residual cardiovascular risk; this is due, in part, to a focus on low-density lipoprotein cholesterol alone and neglect of other important aspects of lipoprotein metabolism. A more refined lipoprotein analysis will provide additional information on the accumulation of very low-density lipoproteins, intermediate density lipoproteins, chylomicrons, chylomicron-remnants and Lp(a) concentrations. Instead of measuring the cholesterol and triglyceride content of the lipoproteins, measurement of their apolipoproteins (apos) is more informative. Apos are either specific for a particular lipoprotein or for a group of lipoproteins. In particular measurement of apos in atherogenic particles is more biologically meaningful than the measurement of the cholesterol concentration contained in these particles. Applying apo profiling will not only improve characterization of the lipoprotein abnormality, but will also improve definition of therapeutic targets. Apo profiling aligns with the concept of precision medicine by which an individual patient is not treated as ‘average’ patient by the average (dose of) therapy. This concept of precision medicine fits the unmet clinical need for stratified cardiovascular medicine. The requirements for clinical application of proteomics, including apo profiling, can now be met using robust mass spectrometry technology which offers desirable analytical performance and standardization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0004563219827620

Cites

187 of 188 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Conceptual view of the proposed paradigm shift from traditional, population-based medicine with prescription roulette due to statin intolerance/poor patient medicine concordance rather than lack of statin efficacy in attaining an LDL-C target and inadequate targeting of the individual lipoprotein risk factors, to precision medicine with personalized therapies, based on biology-driven test results.
Figure 1. Conceptual view of the proposed paradigm shift from traditional, population-based medicine with prescription roulette due to statin intolerance/poor patient medicine concordance rather than lack of statin efficacy in attaining an LDL-C target and inadequate targeting of the individual lipoprotein risk factors, to precision medicine with personalized therapies, based on biology-driven test results.CC BY · PubMed Central
Figure 2. Density and particle size of the different lipoproteins. Their major apolipoprotein constituents are indicated.
Figure 2. Density and particle size of the different lipoproteins. Their major apolipoprotein constituents are indicated.CC BY · PubMed Central
Figure 3. Overview of the relation between reduction in LDL-C and reduction in CVD in genetics and intervention studies. A lifetime reduction of LDL-C by genetic traits (studies indicated by the green dots, mutations indicated) reduces the risk of CVD two to three times more than pharmacological reduction of LDL-C by statin therapy during an average of five years (studies indicated by the blue dots).Source: reproduced with permission from Elsevier.129
Figure 3. Overview of the relation between reduction in LDL-C and reduction in CVD in genetics and intervention studies. A lifetime reduction of LDL-C by genetic traits (studies indicated by the green dots, mutations indicated) reduces the risk of CVD two to three times more than pharmacological reduction of LDL-C by statin therapy during an average of five years (studies indicated by the blue dots).Source: reproduced with permission from Elsevier.129CC BY · PubMed Central
Figure 4. Relative LDL particle size and plasma lipids/lipoprotein concentrations in three patients with identical low LDL-C (1.8 mmol/L) but with discordant non-HDL-C and apoB with regard to desirable treatment targets for very high-risk patients. Patient 1 has all three targets at goal and normal numbers of (predominantly larger sized) LDL particles. Patient 2 with moderate HTG has discordant non-HDL-C above target (2.6 mmol/L) because of increased remnant-cholesterol. Patient 3 also has moderate HTG and increased remnant-cholesterol but concurrently higher apoB concentration than patient 2 because of a high number of sdLDL particles not detected by standard LDL-C measurement.Source: reproduced with permission from American Association for Clinical Chemistry.46
Figure 4. Relative LDL particle size and plasma lipids/lipoprotein concentrations in three patients with identical low LDL-C (1.8 mmol/L) but with discordant non-HDL-C and apoB with regard to desirable treatment targets for very high-risk patients. Patient 1 has all three targets at goal and normal numbers of (predominantly larger sized) LDL particles. Patient 2 with moderate HTG has discordant non-HDL-C above target (2.6 mmol/L) because of increased remnant-cholesterol. Patient 3 also has moderate HTG and increased remnant-cholesterol but concurrently higher apoB concentration than patient 2 because of a high number of sdLDL particles not detected by standard LDL-C measurement.Source: reproduced with permission from American Association for Clinical Chemistry.46CC BY · PubMed Central
Figure 5. (a) ApoCII concentration in 38 patients with very premature STEMI. (b) In this group of patients with very premature CAD, 4 patients with apoCII ≤5 mg/L had a high risk of reinfarction or revascularization over ten years compared to those with apoCII >5 mg/L. (c) In the MISSION Intervention Study the serum concentrations of apoA1, apoB and the apoB/apoA1 ratio were strongly associated with risk of STEMI.Source: reproduced with permission from Elsevier126 and SpringerNature.156
Figure 5. (a) ApoCII concentration in 38 patients with very premature STEMI. (b) In this group of patients with very premature CAD, 4 patients with apoCII ≤5 mg/L had a high risk of reinfarction or revascularization over ten years compared to those with apoCII >5 mg/L. (c) In the MISSION Intervention Study the serum concentrations of apoA1, apoB and the apoB/apoA1 ratio were strongly associated with risk of STEMI.Source: reproduced with permission from Elsevier126 and SpringerNature.156CC BY · PubMed Central
Figure 6. Clinical test-treatment pathways for CVD reduction according to current and new practices.Source: reproduced with permission from Elsevier.7
Figure 6. Clinical test-treatment pathways for CVD reduction according to current and new practices.Source: reproduced with permission from Elsevier.7CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 188 references

Research works printed but not linked: 9

  1. Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383
  2. Superko HR., 2006, Br J Cardiol, 13, 131
  3. Horejsi B, 2000, Physiol Res, 49, S63
  4. Bowden J, 2018, Am J Epidemiol, 187, 2681
  5. Emerging Risk Factors Collaboration, 2012, JAMA, 307, 2499
  6. Tachmazidou I, 2013, Nat Commun, 2872
  7. Mack S, 2017, Sci Rep, 8734
  8. Bodde MC, Clin Res Cardiol
  9. Goldstein J, 2001, The metabolic and molecular basis of inherited disease, 2863

Cited by

See all 43

Metadata

Authors
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M.
Affiliations
  • Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands
  • Leiden University Medical Center (NL)
Corresponding author
Cobbaert, Christa M
Venue
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Published
2019-03-19
Volume
56
Issue
3
Pages
338-356
ISSN
  • 0004-5632 (ISSN-L)
  • 1758-1001
OpenAlex
W2922613166
Cited by
38
References
188
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 1
FWCI
1.13
Type
journal article
Language
en
Open access
Locations
  • Annals of Clinical Biochemistry International Journal of Laboratory Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
dyslipidemia, lipoprotein metabolism, atherogenic lipoproteins, VLDL, intermediate density lipoprotein, chylomicron remnants, lipoprotein(a), residual cardiovascular risk, statin therapy, precision medicine, mass spectrometry, proteomics, cardiovascular risk stratification
MeSH terms
Apolipoproteins, Humans, Risk Assessment, Dyslipidemias, Atherosclerosis, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. https://app.cochat.ai/papers/10.1177/0004563219827620
The paper
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019). Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/0004563219827620

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.